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The tumor microenvironment influences cancer progres-
sion and therapy outcome by mechanisms not yet fully
understood. In this issue of Genes & Development,
Bent and colleagues (pp. 1811–1821) show how chemo-
therapy causes endothelial senescence. Interestingly,
senescent endothelial cells do not mount a typical senes-
cence-associated secretory phenotype but instead acutely
secrete IL-6, promoting chemoresistance. This study un-
veils a physiological switch involving PI3K/AKT/mTOR
signaling that restrains the senescence secretory respons-
es to limit the detrimental consequences of persistent
inflammation.
Senescence is a cellular response that limits the replica-
tion of aged or damaged cells. It is often accompanied by
secretion of various factors collectively known as the sen-
escence-associated secretory phenotype (SASP). The
SASP attracts immune cells to the damaged tissue, which
is beneficial at first glance but can also have adverse side
effects through persistent tissue inflammation or recruit-
ment of immature myeloid progenitors (Coppe et al.
2010).
In previous work, Gilbert and Hemann (2010) had stud-
ied the response of Eμ-myc p19Arf−/− B-cell lymphomas to
doxorubicin treatment. Accumulation of IL-6 and TIMP-1
in the thymus of treated mice provided a prosurvival mi-
croenvironment that slowed lymphoma regression. This
was suggested to be the result of nonmalignant endotheli-
al cells undergoing senescence upon chemotherapy treat-
ment. Here, Bent et al. (2016) used an endothelial-specific
knockout to confirm that hypothesis: Depletion of endo-
thelial IL-6 resulted in decreased thymic tumor burden
upon chemotherapy.
Senescence is thought to have evolved as a mechanism
facilitating tissue remodeling to maintain homeostasis
and prevent damage. Senescence also limits cancer pro-
gression. However, the aberrant accumulation of senes-
cent cells can be detrimental not just during aging but
also in cancer. Factors secreted by senescent cells exert a
range of protumorigenic effects, including facilitating an-
giogenesis, invasion, and metastasis (Coppe et al. 2010).
The role of the SASP in chemoresistance has not been so
well documented, but earlier work also reported that che-
motherapy-induced damage of stromal fibroblasts can pro-
mote therapy resistance via production of WNT16B (Sun
et al. 2012).
We often refer to the secretory responses of senescent
cells with the umbrella term SASP. However, SASP com-
position depends on the senescence inducer or the cell
type undergoing senescence. While many SASP compo-
nents are conserved across different senescent cells, it is
clear that senescent cells can mount different secretory
responses. Interestingly, the paracrine response described
here by Bent et al. (2016) is self-restrained. In spite of the
fact that doxorubicin triggers endothelial senescence, the
secretory response of endothelial cells is limited in dura-
tion and composition when compared with the SASP.
This atypical transient senescence-associated secretory
response has been termed acute stress-associated pheno-
type (ASAP).
Beyond the canonical SASP and the acute ASAP re-
sponse, senescence induced by knocking outCKIα in colo-
rectal cells induces a so-called senescence inflammatory
response (SIR) (Pribluda et al. 2013), more like parainflam-
mation than canonical SASP. Dysfunctional mitochon-
dria also trigger senescence with a distinct secretory
phenotype termed MIDAS (mitochondrial dysfunction-
associated secretome) (Wiley et al. 2015). A systematic ap-
proach is needed to understand the commonalities and
differences of the various secretomes of senescent cells.
To understand how ASAP is established and restricted,
the investigators used an in vitro system. Human umbili-
cal vein endothelial cells (HUVECs) treated with doxoru-
bicin acutely produced IL-6 and a restricted set of secreted
factors followed by cell cycle arrest and the up-regulation
of conventional markers of senescence. Induction of
ASAP in HUVECs was dependent on reactive oxygen
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species (ROS)-induced activation of p38 but not onNF-κB,
a key regulator of the SASP. Two recent studies showed
that mTOR controls the translation of IL-1α and MAP-
KAPK2 (a kinase downstream from p38) to regulate the
SASP (Herranz et al. 2015; Laberge et al. 2015). Moreover,
PI3K/AKT/mTOR signaling has also been shown to regu-
late a paracrine response responsible for melanoma resis-
tance to BRAF inhibitors (Obenauf et al. 2015). In light
of these findings, Bent et al. (2016) explored the role of
the PI3K/AKT/mTOR pathway on ASAP regulation. Sur-
prisingly, they found that the pathway was repressed as
cells became senescent (Fig. 1). The investigators hypoth-
esized that this physiological mTOR inactivation under-
scores a shielding mechanism restraining the duration of
IL-6 secretion to avoid the long-term side effects of chron-
ic inflammation. Consistent with this, the mTORC1 in-
hibitor rapamycin did not abolish ASAP. It would be
interesting to test whether p38 inhibition or ROS scaven-
gers wouldmimic genetic depletion of IL-6 and prevent re-
sistance to chemotherapy.
The benefit of inflammatory responses upon damage is
restricted in time, and, consequently, organisms have
evolved mechanisms to counteract overt inflammation
and maintain tissue homeostasis. The accumulation of
senescent cells with age results in persistent inflamma-
tion that contributes to a tumor-permissive environment.
Very recently, it was shown that sFRP2 secreted fromaged
senescent fibroblasts drives therapy resistance of melano-
ma cells and promotes metastasis (Kaur et al. 2016).
Whether this is because aged cells have lost their ability
to restrain the SASP merits further investigation.
The secretomes of senescent cells can mediate many
functions (either beneficial or detrimental). Recent evi-
dence suggests that they can also contribute to acquired
chemoresistance. In this regard, the present study shows
that doxorubicin-induced endothelial cell senescence in
the thymus is the main culprit of IL-6–driven protection
of lymphomas against chemotherapy. This response is re-
strained by the gradual down-regulation of the mTOR
pathway. Previously, inhibition of the mTOR pathway
has been proposed as a potential strategy to repress the
SASP (Herranz et al. 2015; Laberge et al. 2015). The pre-
sent study suggests that the PI3K/AKT/mTOR pathway
might be a physiological switch that controls the duration
of paracrine responses to avoid the detrimental effects
caused by chronic low-grade inflammation.
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Figure 1. The ASAP is a self-limited senescence secretory phe-
notype. Bent et al. (2016) described an acute senescence secretory
phenotype resulting from chemotherapy and termed it the ASAP.
ASAP induction relies on p38 and is innately resolved by mTOR
inhibition. The SASP is a self-sustained response that relies also
onNF-κB activation. In contrast to theASAP, the SASP is a chron-
ic response and involves secretion of awider range of factors.Mul-
ticolored dots represent secreted factors.
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